» Articles » PMID: 10992368

Transurethral Resection of the Prostate Among Medicare Beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2000 Sep 19
PMID 10992368
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We examine the epidemiology and associated risks of transurethral resection of the prostate among Medicare beneficiaries for the period 1984 to 1997.

Materials And Methods: We used hospital claims for transurethral resection of the prostate from a 20% national sample of Medicare beneficiaries for the period 1991 to 1997. Risk of mortality and reoperation were evaluated using life table methods and compared to those for the period 1984 to 1990. We also examined the association between surgical volume and adverse outcomes following resection using unique urologist identifier codes from the 1997 part B Medicare claims.

Results: Compared to 1984 to 1990, age adjusted rates of transurethral resection for benign prostatic hyperplasia (BPH) during 1991 to 1997 declined by approximately 50% for white (14.6 to 6.72/1,000) and 40% for black (11.8 to 6.58/1,000) men. Of the men who underwent resection for BPH during the recent period 53% were 75 years old or older but 30-day mortality in men 70 years old or older was significantly lower than that in 1984 to 1990. Since 1987 the 5-year risk for reoperation following transurethral resection for BPH has remained 5%. For resection performed in 1997 we observed no statistically significant association between urologist surgical volume and risks of reoperation or 30-day mortality.

Conclusions: Compared to the peak period of its use in the 1980s, older men are now undergoing transurethral resection of the prostate. Nevertheless, outcomes for men 65 years old or older continue to be good.

Citing Articles

Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study.

Kaplan S, Kaufman Jr R, Mueller T, Elterman D, Chughtai B, Rukstalis D Prostate Cancer Prostatic Dis. 2023; 27(3):485-491.

PMID: 37884615 PMC: 11319193. DOI: 10.1038/s41391-023-00741-8.


Enucleation of the prostate as retreatment for recurrent or residual benign prostatic obstruction: a systematic review and a meta-analysis.

Pyrgidis N, Mykoniatis I, Lusuardi L, Schulz G, Sokolakis I, Stief C Prostate Cancer Prostatic Dis. 2023; 26(4):693-701.

PMID: 37193777 DOI: 10.1038/s41391-023-00677-z.


Correlation of Postoperative Outcomes According to the Amount of Prostatic Tissue Removed in Patients Undergoing Transurethral Resection of the Prostate.

Turgut O, Erbagci A, Bayrak O, Seckiner I, Erturhan S, Sen H Cureus. 2023; 15(1):e34451.

PMID: 36874733 PMC: 9980425. DOI: 10.7759/cureus.34451.


Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review.

Malde S, Lam W, Adwin Z, Hashim H BJUI Compass. 2022; 2(4):238-259.

PMID: 35475299 PMC: 8988658. DOI: 10.1002/bco2.74.


Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: A nationwide population-based cohort study.

Kim D, Park J, Yang W, Doo S, Kim J, Song Y Prostate Int. 2022; 9(4):215-220.

PMID: 35059360 PMC: 8740390. DOI: 10.1016/j.prnil.2021.08.002.